GSK, Sanofi and Haleon ‘facing billions of dollars in Zantac liability’
GSK, its consumer health spin-off Haleon and Sanofi could be on the hook for billions of dollars in potential damages over Zantac, a gastrointestinal drug pulled from the market in 2020 after it was linked to cases of cancer. That’s the conclusion of analysts at Morgan Stanley, Deutsche Bank and UBS, who have all issued …
GSK, Sanofi and Haleon ‘facing billions of dollars in Zantac liability’ Read More »